Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Host: Arshad M. Khanani, MD, MA
\n\n Guest: Karl Csaky, MD, PhD
\n\n Guest: Christina Y. Weng, MD, MBA, FASRS
\n\n\n \n
Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways\u2014VEGF-A and angiopoietin-2 (Ang-2)\u2014is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members\u2019 own practices.